Developing new CRISPR/Cas9-based genome editing tools will enhance innovative therapeutic products and the pathway to clinical programs. However, current obstacles in genome editing include high error rates, toxicity from production impurities, and strict regulatory concerns. Therefore, offering the optimal foundation for gene-to-protein services, from process development optimization to scale-up manufacturing, is critical to accelerating the therapeutic program to success. Nanoplasmid next-generation vector technology provides the fundamental platform for extending and increasing expression, lowering transfection toxicity, and eliminating the risk of transferred antibiotic resistance to patients. In this GEN webinar, our distinguished guests, Max Sellman and Dr. Jim Williams, will discuss features and data on using Nanoplasmids as an HDR template paired with Aldevron Cas9 nucleases, delivering premier tools for gene editing in CAR-T applications.